Back to Search Start Over

25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial

Authors :
Jean-Philippe Galanaud
Céline Genty-Vermorel
Marie-Thérèse Barrellier
François Becker
Violaine Jabbour
Sophie Blaise
Alessandra Bura-Rivière
Alexa Comte
Claire Grange
Herve Guenneguez
Mario Maufus
Pierre Ouvry
Cécile Richaud
Carole Rolland
Jeannot Schmidt
Marie-Antoinette Sevestre
François Verrière
Jean-Luc Bosson
Olivier Pichot
Hervé Guenneguez
Anna Di Maio
Francis Couturaud
Marc Danguy Des Déserts
Patrick Mismetti
Damien Laneelle
Béatrice Terriat
Audrey Stansal
Myriam Martin
Constant Quashie
Mickaël Bonaldi
Patrick Lanoye
Francine Ponchaux-Crépin
Toufek Berremili
Marie-Antoinette Sevestre-Pietri
Santhi Samy-Modeliar
Azeddine Addala
Luc Toffin
Bruno Rouquet
Maïlys Michot-Casbas
Guillaume Lacaze
Pierre-Marie Roy
Cécile Durant
Anne-Laure Baldassini-Esquis
Alain Cazanave
Damien Rouvière
Hélène Skolka
Tewfik Salem
Jean-Michel Monsallier
Benoit Roger
Thien-Quang Tra
Mutendi Kalolwa
Antoine Diard
Marc Lambert
Mebarka Taiar
Céline Gaudout
Sylvain Ancey
Christine Jurus
Source :
The Lancet Haematology. 9:e886-e896
Publication Year :
2022
Publisher :
Elsevier BV, 2022.

Abstract

The optimal strength of compression needed to prevent post-thrombotic syndrome (PTS) after a proximal deep vein thrombosis (DVT) is debated. We aimed to assess whether 25 mm Hg elastic compression stockings (ECS) are non-inferior to 35 mm Hg ECS in preventing PTS after a DVT.In this multicentre, double-blind, non-inferiority, randomised controlled trial, we enrolled adults (≥18 years) with a first ipsilateral proximal DVT attending 46 French vascular medicine hospital departments or private practices. Participants were randomly allocated (1:1, stratified by centre, age, and sex; with varying block sizes of two and four) to wear 25 mm Hg or 35 mm Hg ECS for 2 years. The primary outcome was the cumulative rate of PTS 2 years after inclusion, defined by a Villalta scale (≥5). Efficacy was assessed by intention-to-treat and in eligible participants who had complete primary outcome data. A per-protocol analysis was also conducted among compliant patients as a secondary outcome measure. Safety was assessed in all participants who used ECS at least once, and for which we have at least some tolerance information during follow-up. The margin for non-inferiority was 12·5%. This study is registered with ClinicalTrials.gov, NCT01578122, and has been completed.Between June 28, 2012, and July 21, 2017, we enrolled 341 eligible participants who consented to randomisation. 233 (68%) were men and median age was 59 years (IQR 45-70). Collection of ethnicity and race as a routine research variable is not authorised in France. Median follow-up was 735 days (IQR 721-760). 249 (73%) had complete data at 2 years. For the primary analysis, 40 (31%) of 129 participants with complete data in the 25 mm Hg ECS group and 40 (33%) of 120 in the 35 mm Hg group had PTS (absolute difference -2·3% [90% CI -12·1 to 7·4], pAlthough we did not reach the prespecified sample size, our results suggest that 25 mm Hg ECS are non-inferior to 35 mm Hg ECS in preventing PTS. Larger more powerful studies are needed.Laboratoires Innothera, France.

Details

ISSN :
23523026
Volume :
9
Database :
OpenAIRE
Journal :
The Lancet Haematology
Accession number :
edsair.doi.dedup.....e494fe5a524384f55e3b5198363b15b6